Subjects were randomized ( @ : @ : @ : @ ) to one of three subcutaneous secukinumab @-mg induction regimens -LSB- Single ( Week @ ) , Monthly ( Weeks @ , @ , @ ) , Early ( Weeks @ , @ , @ , @ ) -RSB- or placebo .